nach oben

Breast Cancer Research

Erschienen in:

01.05.2008 | Poster presentation

Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer

verfasst von: M Cummings, L Maraqa, MB Peter, AM Shaaban, AM Hanby, MA Hull, V Speirs

Erschienen in: Breast Cancer Research | Sonderheft 2/2008

Einloggen, um Zugang zu erhalten

Excerpt

Tamoxifen has been the principal endocrine therapy for estrogen receptor alpha (ERα)-positive breast cancer patients and still remains the therapy of choice in the premenopausal setting. However, resistance and recurrence remain a serious problem. Our previous work has indicated that 15-hydroxyprostaglandin dehydrogenase (15-PGDH) was significantly down-regulated in two, independently derived, tamoxifen-resistant (TAMr) MCF-7 derivatives compared with sensitive controls [1]. 15-PGDH is the key enzyme for the biological inactivation of prostaglandins, and has been shown to be a tumour suppressor in breast cancer. However, a role for 15-PGDH downregulation in endocrine resistance has not previously been identified. …

Scott DJ, Parkes AT, Ponchel F, Cummings M, Poola I, Speirs V: Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. Int J Oncol. 2007, 31: 557-565.PubMed

Titel: Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer
verfasst von: M Cummings
L Maraqa
MB Peter
AM Shaaban
AM Hanby
MA Hull
V Speirs
Publikationsdatum: 01.05.2008
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe Sonderheft 2/2008
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1914

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Downregulation of 15-hydroxyprostaglandin dehydrogenase in hormone-resistant breast cancer

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2008

Homeopathy service in an NHS hospital breast cancer clinic: outcome study

High-throughput optical proteomics and breast cancer patient profiling: novel applications to individualise prognosis and treatment

Detection of gene amplification in matched tumour and plasma DNA from breast cancer patients by quantitative PCR

Regulation of estrogen receptor beta by 5' untranslated regions in breast carcinogenesis

Living with genetic risk of breast cancer: what have we learned?

D133p53 isoform is a direct p53 target gene that modulates p53 tumour suppressor activity

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie